Skip to main content
      #EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 days 15 hours ago
      #EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃 https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w
      RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow a

      Dr. John Cush RheumNow

      4 days 15 hours ago
      RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
      @RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstra

      Jiha Lee JihaRheum

      5 days 2 hours ago
      @RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstracts https://t.co/smN8hg51nj
      🏠 Take Home Messages from the early #axSpA session

      🔺 Earlier diagnosis is possible and better
      🔺 Early axSpA is

      Nelly ZIADE 🍀 Nellziade

      5 days 2 hours ago
      🏠 Take Home Messages from the early #axSpA session 🔺 Earlier diagnosis is possible and better 🔺 Early axSpA is not synonymous to mild 🔺 Longitudinally, early axSpA is heterogeneous 🔺 MRI has transformed the field ❗️Beware of pitfalls #EULAR2026 @RheumNow https://t.co/IhGQSxssyd
      The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and classification criteria for the Anti-Synthetase Syndrome. Here are but a few of my favorites from a list of many quality sessions.
      Remember
      Babies of pts on chronic #immunosuppression with #SARDs

      ❎delay #vaccinations til 6/12
      For safety & to m

      Janet Pope Janetbirdope

      5 days 8 hours ago
      Remember Babies of pts on chronic #immunosuppression with #SARDs ❎delay #vaccinations til 6/12 For safety & to mount sufficient response #rotovirus #vaccine is Ok before 6 months or vaccine is ineffective Pts w #SARDs need #COVID shots @RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY
      What’s new with the 2026 update of reco for vax in AIIRD?
      Vaccinate as soon as possible
      Non-live vaccines are safe
      Ho

      sheila RHEUMarampa

      5 days 8 hours ago
      What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI
      #EULAR2026 #SARD #vaccination #recommendations
      I think 🤔
      ✅proactive➡️take responsibility
      ✅close gap
      ✅most

      Janet Pope Janetbirdope

      5 days 8 hours ago
      #EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
      Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in he

      Jiha Lee JihaRheum

      5 days 8 hours ago
      Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246
      Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults.
      "Steroids and Me"

      Jiha Lee JihaRheum

      5 days 8 hours ago
      Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults. "Steroids and Me" (Sam) provides online patient education ~5 minutes. @RheumNow #EULAR2026 POS1388
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome
      He emphasizes the inportanc

      sheila RHEUMarampa

      5 days 8 hours ago
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW
      T2T works in elderly-onset #RA. tREACH trial (n=425): EORA (mean age 73) achieve LDA similar to young-onset RA; often w

      Jiha Lee JihaRheum

      5 days 9 hours ago
      T2T works in elderly-onset #RA. tREACH trial (n=425): EORA (mean age 73) achieve LDA similar to young-onset RA; often with lower treatment intensity when seronegative. Drug tolerability comparable in EORA vs YORA despite more comorbidities. @RheumNow #EULAR2026 POS1326 https://t.co/tKRki2KLzP
      B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
      ×